Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Poitiers – page 32

619 clinical trials in Poitiers, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Poitiers at a glance
619
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

619 trials in Poitiers

Open in trial search

Cholangiocarcinoma

Not recruiting

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fondation Franc.Cancerologie Digestive

Arteriosclerosis

Not recruiting

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Essential tremor

Not recruiting

Study on the Effectiveness of BP1.4979 for Adults with Essential Tremor

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Coronavirus infection

Not recruiting

Study on COVID-19 Prevention Using Sipavibart and Cilgavimab for Patients with Weakened Immune Systems

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Cilgavimab
  • Sponsor:AstraZeneca AB

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Institut De Cancerologie De L Ouest

VEXAS syndrome

Not recruiting

Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Sobi Inc.

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Itepekimab for Adults with Chronic Rhinosinusitis and Nasal Polyps

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Primary myelofibrosis

Not recruiting

Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Symptom Changes in Adults with Chronic Rhinosinusitis with Nasal Polyps Using Tezepelumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Mastocytosis

Not recruiting

Study on the Effectiveness and Safety of Masitinib for Patients with Severe Systemic Mastocytosis Unresponsive to Treatment

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
  • Sponsor:Ab Science

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Colon cancer

Not recruiting

Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Poitiers

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and various advanced cancers. Studies are evaluating novel therapeutic combinations and treatment strategies for better patient outcomes.

  • Advanced Gastric Cancer Treatments
  • Pancreatic Adenocarcinoma Therapy
  • Myelodysplastic Syndromes

Several trials are investigating targeted therapies and immunotherapy approaches for various cancer types.

02 Neurological Studies

Research focusing on essential tremor treatments and innovative therapeutic approaches. Clinical trials are evaluating new medications for movement disorders.

  • Movement Disorders
  • Neurological Conditions
  • Early Psychosis Treatment

Studies aim to improve patient quality of life through novel therapeutic interventions.

03 Transplant Medicine

Advanced research in kidney transplantation and post-transplant care, including studies on antibody-mediated rejection prevention and treatment strategies.

  • Organ Transplantation
  • Immunosuppression Protocols
  • Rejection Prevention

Trials focus on improving long-term outcomes for transplant recipients.

04 Critical Care Medicine

Studies evaluating postoperative care and pain management in critical care settings, including innovative approaches to patient comfort and recovery.

  • Pain Management
  • Postoperative Care
  • Patient Comfort Optimization

Research aims to enhance patient comfort and recovery in intensive care settings.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.